Free tools, free alerts. Create a free account to get sector-matched alerts and save your searches.
Create free account →
Recent regulatory updates from NAFDAC focus on strengthening pharmaceutical oversight through mandatory clinical trial training, blacklisting non-compliant foreign suppliers, and placing certain products on watchlist, while also expanding the pharmacist workforce via a reserve group. For Nigerian SMBs in healthcare, pharmaceuticals, and related sectors, these changes signal stricter compliance requirements and heightened scrutiny of supply chains, necessitating proactive verification of products and suppliers.
Pharmaceuticals
Healthcare
Import/Export
Retail/Distribution
Clinical Research
NAFDAC and NHREC Announce New Dates for Mandatory Stakeholders Training on Clinical Trial Regulations in Nigeria
NAFDAC
NAFDAC and NHREC have rescheduled mandatory training on clinical trial regulations for stakeholders.
SMBs involved in clinical trials or pharmaceutical research must ensure staff attend the training to remain compliant with regulatory requirements.
Public Notice on Blacklisting Ayrtons Saunders Ltd, UK
NAFDAC
NAFDAC has blacklisted Ayrtons Saunders Ltd, UK, and its products, prohibiting importation, distribution, and sale in Nigeria.
SMBs importing or distributing products from this company must immediately cease and verify their supply chains to avoid regulatory penalties.
Public Alert No. 043/2026-NAFDAC Places Products Marketed by Mofus Nigeria Ltd on Watchlist Pending Regulatory Investigation
NAFDAC
NAFDAC has placed products marketed by Mofus Nigeria Ltd on a watchlist pending investigation, urging stakeholders to be cautious.
SMBs dealing with Mofus Nigeria Ltd products should suspend sales and await further regulatory guidance to avoid legal risks.
Inauguration Ceremony of the NAFDAC Pharmacist Reserve Group
NAFDAC
NAFDAC inaugurated a Pharmacist Reserve Group of 600 pharmacists to provide voluntary service.
SMBs in healthcare may benefit from increased pharmacist availability for temporary or voluntary roles, potentially easing staffing shortages.
Address by Prof. Mojisola Christianah Adeyeye at the 49th Annual International Conference of the Chemical Society of Nigeria
NAFDAC
NAFDAC DG highlighted innovations in medicinal and pharmaceutical chemistry for affordable healthcare delivery.
SMBs in pharmaceutical manufacturing and research should note potential future regulatory focus on innovation and affordability, which may influence product development and approval processes.
Increased regulatory scrutiny on pharmaceutical supply chains and imported products.
Mandatory training requirements for clinical trial stakeholders.
Expansion of pharmacist workforce through reserve group may alleviate staffing gaps.
Emphasis on innovation in pharmaceutical chemistry could lead to new opportunities for compliant SMBs.
Blacklisting and watchlisting of specific companies signal need for rigorous supplier due diligence.
1
Verify that your product portfolio does not include items from Ayrtons Saunders Ltd or Mofus Nigeria Ltd; remove them from shelves if present.
2
Register for and attend the NAFDAC/NHREC mandatory training on clinical trial regulations if involved in clinical research.
3
Conduct a thorough review of your supply chain to ensure all suppliers are NAFDAC-compliant and not blacklisted.
4
Stay updated with NAFDAC public alerts and notices to avoid inadvertently dealing in unauthorized products.
5
Consider leveraging the NAFDAC Pharmacist Reserve Group for temporary staffing needs if applicable.